Medtronic Neuro Gets Warning Letter, FDA Wants to Meet on Motor Flaws

Devices & Diagnostics Letter
Medtronic’s neuromodulation unit has received an FDA warning letter on allegations the business segment did not handle complaints properly, among other corrective and preventive action (CAPA) violations.

To View This Article:


Subscribe To Devices & Diagnostics Letter

Buy This Article Now

Add this article to your cart for $120.00